Delivery of nucleic acids, such as mRNA, to immune cells has become a major focus in the
past decade with ionizable lipid nanoparticles (LNPs) emerging as a clinically-validated …

Lipid nanoparticles (LNPs) have emerged as a viable, clinically-validated platform for the
delivery of mRNA therapeutics. LNPs have been utilized as mRNA delivery systems for …

Ionizable lipid‐based nanoparticles (LNPs) are the most advanced non‐viral drug delivery
systems for RNA therapeutics and vaccines. However, cell type‐specific, extrahepatic mRNA …

The broad clinical application of mRNA therapeutics has been hampered by a lack of
delivery vehicles that induce protein expression in extrahepatic organs and tissues …

RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable
diseases and genetic disorders by regulating disease-related gene expression. The …

Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

Stereochemistry can alter small-molecule pharmacokinetics, safety and efficacy. However, it
is unclear whether the stereochemistry of a single compound within a multicomponent …

Endosomal sequestration of lipid-based nanoparticles (LNPs) remains a formidable barrier
to delivery. Herein, structure-activity analysis of cholesterol analogues reveals that …

The last few years have witnessed a great advance in the development of nonviral systems
for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most …

Background Cancer remains a serious health concern worldwide, and different approaches
are being developed for its treatment. The strategy to use the immune system as an …